All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Striving to maintain the Hatch-Waxman balance between innovation and access to affordable prescription drugs, the Massachusetts Supreme Judicial Court closed the door on holding a brand manufacturer responsible for state failure-to-warn claims, due to negligence, stemming from use of a generic product.